Modification of cytokine-induced killer cells with chimeric antigen receptors (CARs) enhances antitumor immunity to epidermal growth factor receptor (EGFR)-positive malignancies

Cancer Immunology, Immunotherapy

Volumn 64, Issue 12, 2015, Pages 1517-1529

  Ren, Xuequn ^a   Ma, Wanli ^a   Lu, Hong ^a   Yuan, Lei ^b   An, Lei ^a   Wang, Xicai ^c   Cheng, Guanchang ^a   Zuo, Shuguang ^a  

^a HENAN UNIVERSITY   (China)

^b Luohe Medical College   (China)

^c KUNMING MEDICAL UNIVERSITY   (China)

Author keywords

Adoptive cellular immunotherapy; Chimeric antigen receptor; Cytokine induced killer cells; Epidermal growth factor receptor

Indexed keywords

CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GAMMA INTERFERON; INTERLEUKIN 2; LENTIVIRUS VECTOR; EGFR PROTEIN, HUMAN; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; LYMPHOCYTE ANTIGEN RECEPTOR;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER SURVIVAL; CELL CULTURE; CELL SURFACE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOKINE INDUCED KILLER CELL; CYTOKINE RELEASE; EFFECTOR CELL; FEMALE; FLOW CYTOMETRY; GASTRIC CANCER CELL LINE; GENE OVEREXPRESSION; GENE SILENCING; HT 29 CELL LINE; HUMAN; HUMAN CELL; LUNG CANCER CELL LINE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHENOTYPE; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM; VIRAL GENE THERAPY; WESTERN BLOTTING; ANIMAL; CYTOLOGY; GENETICS; IMMUNOLOGY; METABOLISM; MORTALITY; NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CYTOKINE-INDUCED KILLER CELLS; HETEROGRAFTS; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-2; MICE; NEOPLASMS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, ANTIGEN; RECEPTORS, INTERFERON;

EID: 84947026455     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1757-6     Document Type: Article

References (33)

1. Nedergaard MK, Hedegaard CJ, Poulsen HS (2012) Targeting the epidermal growth factor receptor in solid tumor malignancies. BioDrugs 26(2):83–99. doi:10.2165/11599760-000000000-00000
2. Arteaga CL (2002) Epidermal growth factor receptor dependence in human tumors: more than just expression? Oncologist 7(Suppl 4):31–39
3. Ciardiello F, Tortora G (2008) EGFR antagonists in cancer treatment. N Engl J Med 358(11):1160–1174. doi:10.1056/NEJMra0707704
4. Carteni G, Fiorentino R, Vecchione L, Chiurazzi B, Battista C (2007) Panitumumab a novel drug in cancer treatment. Ann Oncol 18(Suppl 6):vi16–vi21. doi:10.1093/annonc/mdm218
5. Ciardiello F, Tortora G (2001) A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. Clin Cancer Res 7(10):2958–2970
6. Bulgaru AM, Mani S, Goel S, Perez-Soler R (2003) Erlotinib (Tarceva): a promising drug targeting epidermal growth factor receptor tyrosine kinase. Expert Rev Anticancer Ther 3(3):269–279. doi:10.1586/14737140.3.3.269
7. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, Seto T, Satouchi M, Tada H, Hirashima T, Asami K, Katakami N, Takada M, Yoshioka H, Shibata K, Kudoh S, Shimizu E, Saito H, Toyooka S, Nakagawa K, Fukuoka M, West Japan Oncology G (2010) Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial. Lancet Oncol 11(2):121–128. doi:10.1016/S1470-2045(09)70364-X
8. Ohashi K, Maruvka YE, Michor F, Pao W (2013) Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol 31(8):1070–1080. doi:10.1200/JCO.2012.43.3912
9. Chong CR, Janne PA (2013) The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med 19(11):1389–1400. doi:10.1038/nm.3388
10. Gutgemann S, Frank S, Strehl J, Schmidt-Wolf IG (2007) Cytokine-induced killer cells are type II natural killer T cells. Ger Med Sci 5:Doc07
11. Linn YC, Hui KM (2010) Cytokine-induced NK-like T cells: from bench to bedside. J Biomed Biotechnol 2010:435745. doi:10.1155/2010/435745
12. Schmidt TL, Negrin RS, Contag CH (2014) A killer choice for cancer immunotherapy. Immunol Res 58(2–3):300–306. doi:10.1007/s12026-014-8507-2
13. Yoon SH, Lee JM, Woo SJ, Park MJ, Park JS, Kim HS, Park MY, Sohn HJ, Kim TG (2009) Transfer of Her-2/neu specificity into cytokine-induced killer (CIK) cells with RNA encoding chimeric immune receptor (CIR). J Clin Immunol 29(6):806–814. doi:10.1007/s10875-009-9308-6
14. Cartellieri M, Bachmann M, Feldmann A, Bippes C, Stamova S, Wehner R, Temme A, Schmitz M (2010) Chimeric antigen receptor-engineered T cells for immunotherapy of cancer. J Biomed Biotechnol 2010:956304. doi:10.1155/2010/956304
15. Jena B, Dotti G, Cooper LJ (2010) Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor. Blood 116(7):1035–1044. doi:10.1182/blood-2010-01-043737
16. Porter DL, Levine BL, Kalos M, Bagg A, June CH (2011) Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia. N Engl J Med 365(8):725–733. doi:10.1056/NEJMoa1103849
17. Zuo S, Liu C, Wang J, Wang F, Xu W, Cui S, Yuan L, Chen X, Fan W, Cui M, Song G (2012) IGFBP-rP1 induces p21 expression through a p53-independent pathway, leading to cellular senescence of MCF-7 breast cancer cells. J Cancer Res Clin Oncol 138(6):1045–1055. doi:10.1007/s00432-012-1153-y
18. Dudley ME, Rosenberg SA (2003) Adoptive-cell-transfer therapy for the treatment of patients with cancer. Nat Rev Cancer 3(9):666–675. doi:10.1038/nrc1167
19. Sangiolo D (2011) Cytokine induced killer cells as promising immunotherapy for solid tumors. J Cancer 2:363–368
20. Sangiolo D, Mesiano G, Carnevale-Schianca F, Piacibello W, Aglietta M, Cignetti A (2009) Cytokine induced killer cells as adoptive immunotherapy strategy to augment graft versus tumor after hematopoietic cell transplantation. Expert Opin Biol Ther 9(7):831–840. doi:10.1517/14712590903005552
21. Marin V, Dander E, Biagi E, Introna M, Fazio G, Biondi A, D’Amico G (2006) Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy. Exp Hematol 34(9):1219–1229. doi:10.1016/j.exphem.2006.05.004
22. Schlimper C, Hombach AA, Abken H, Schmidt-Wolf IG (2012) Improved activation toward primary colorectal cancer cells by antigen-specific targeting autologous cytokine-induced killer cells. Clin Dev Immunol 2012:238924. doi:10.1155/2012/238924
23. Marin V, Pizzitola I, Agostoni V, Attianese GM, Finney H, Lawson A, Pule M, Rousseau R, Biondi A, Biagi E (2010) Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors. Haematologica 95(12):2144–2152. doi:10.3324/haematol.2010.026310
24. Song DG, Ye Q, Carpenito C, Poussin M, Wang LP, Ji C, Figini M, June CH, Coukos G, Powell DJ Jr (2011) In vivo persistence, tumor localization, and antitumor activity of CAR-engineered T cells is enhanced by costimulatory signaling through CD137 (4-1BB). Cancer Res 71(13):4617–4627. doi:10.1158/0008-5472.CAN-11-0422
25. Zhou X, Li J, Wang Z, Chen Z, Qiu J, Zhang Y, Wang W, Ma Y, Huang N, Cui K, Li J, Wei YQ (2013) Cellular immunotherapy for carcinoma using genetically modified EGFR-specific T lymphocytes. Neoplasia 15(5):544–553
26. Zhao Y, Wang QJ, Yang S, Kochenderfer JN, Zheng Z, Zhong X, Sadelain M, Eshhar Z, Rosenberg SA, Morgan RA (2009) A herceptin-based chimeric antigen receptor with modified signaling domains leads to enhanced survival of transduced T lymphocytes and antitumor activity. J Immunol 183(9):5563–5574. doi:10.4049/jimmunol.0900447
27. Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C, Foddai ML, Lorusso D, Martinelli E, Vacca M, Ipsevich F, Nuti M, Scambia G, Pierelli L (2012) Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 14(7):841–850. doi:10.3109/14653249.2012.681038
28. Han EQ, Li XL, Wang CR, Li TF, Han SY (2013) Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges. J Hematol Oncol 6:47. doi:10.1186/1756-8722-6-47
29. Savoldo B, Ramos CA, Liu E, Mims MP, Keating MJ, Carrum G, Kamble RT, Bollard CM, Gee AP, Mei Z, Liu H, Grilley B, Rooney CM, Heslop HE, Brenner MK, Dotti G (2011) CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients. J Clin Invest 121(5):1822–1826. doi:10.1172/JCI46110
30. Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, Samanta M, Lakhal M, Gloss B, Danet-Desnoyers G, Campana D, Riley JL, Grupp SA, June CH (2009) Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther 17(8):1453–1464. doi:10.1038/mt.2009.83
31. Hombach AA, Abken H (2011) Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling. Int J Cancer 129(12):2935–2944. doi:10.1002/ijc.25960
32. Till BG, Jensen MC, Wang J, Qian X, Gopal AK, Maloney DG, Lindgren CG, Lin Y, Pagel JM, Budde LE, Raubitschek A, Forman SJ, Greenberg PD, Riddell SR, Press OW (2012) CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results. Blood 119(17):3940–3950. doi:10.1182/blood-2011-10-387969
33. Hombach AA, Rappl G, Abken H (2013) Arming cytokine-induced killer cells with chimeric antigen receptors: CD28 outperforms combined CD28-OX40 “super-stimulation”. Mol Ther 21(12):2268–2277. doi:10.1038/mt.2013.192